Different Factors Associated with 2-Year Outcomes in Patients with Branch versus Central Retinal Vein Occlusion Treated with Ranibizumab期刊界 All Journals 搜尽天下杂志传播学术成果专业期刊搜索期刊信息化学术搜索

Different Factors Associated with 2-Year Outcomes in Patients with Branch versus Central Retinal Vein Occlusion Treated with Ranibizumab

Authors:	Raafay Sophie Pin-wen Wang Roomasa Channa Carlos Quezada-Ruiz Ann Clark Peter A. Campochiaro

Affiliation:	1. Medical College of Wisconsin, Department of Ophthalmology and Visual Sciences, Milwaukee, Wisconsin;2. Genentech, Inc., South San Francisco, California;3. Baylor College of Medicine, Department of Ophthalmology, Houston, Texas;4. The Wilmer Eye Institute, Johns Hopkins University, Baltimore, Maryland

Abstract:

Keywords:	Correspondence: Peter A. Campochiaro, MD, Maumenee 719, The Wilmer Eye Institute, The Johns Hopkins University School of Medicine, 600 North Wolfe St., Baltimore, MD 21287-9277. BCVA best-corrected visual acuity BRAVO Ranibizumab for the Treatment of Macular Edema following Branch Retinal Vein Occlusion: Evaluation of Efficacy and Safety BRVO branch retinal vein occlusion CI confidence interval CRUISE Ranibizumab for the Treatment of Macular Edema after Central Retinal Vein Occlusion Study: Evaluation of Efficacy and Safety CRVO central retinal vein occlusion CST central subfield thickness DME diabetic macular edema ETDRS Early Treatment Diabetic Retinopathy Study FA fluorescein angiography FP fundus photograph HORIZON An Open-Label, Multicenter Extension Study to Evaluate the Safety and Tolerability of Ranibizumab in Subjects With Choroidal Neovascularization Secondary to Age-Related Macular Degeneration or Macular Edema Secondary to Retinal Vein Occlusion Who Have Completed a Genentech-Sponsored Ranibizumab Study ME macular edema OPP ocular perfusion pressure OR odds ratio RBZ ranibizumab RVO retinal vein occlusion VEGF vascular endothelial growth factor
本文献已被 ScienceDirect 等数据库收录！

设为首页 | 免责声明 | 关于勤云 | 加入收藏